Sunshine Biopharma, Inc.
SBFM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $34,874 | $24,093 | $4,346 | $228 |
| % Growth | 44.7% | 454.4% | 1,802.6% | – |
| Cost of Goods Sold | $24,204 | $15,754 | $2,649 | $118 |
| Gross Profit | $10,670 | $8,339 | $1,697 | $111 |
| % Margin | 30.6% | 34.6% | 39% | 48.4% |
| R&D Expenses | $934 | $1,856 | $812 | $672 |
| G&A Expenses | $13,997 | $10,096 | $8,900 | $1,866 |
| SG&A Expenses | $14,937 | $10,830 | $9,478 | $1,866 |
| Sales & Mktg Exp. | $940 | $734 | $578 | $0 |
| Other Operating Expenses | $611 | $439 | $80 | $13 |
| Operating Expenses | $16,482 | $13,124 | $10,371 | $2,551 |
| Operating Income | -$5,812 | -$4,785 | -$27,001 | -$2,440 |
| % Margin | -16.7% | -19.9% | -621.3% | -1,068.2% |
| Other Income/Exp. Net | $443 | $674 | $490 | -$9,996 |
| Pre-Tax Income | -$5,369 | -$4,111 | -$26,511 | -$12,436 |
| Tax Expense | -$235 | $395 | $233 | $0 |
| Net Income | -$5,134 | -$4,506 | -$26,744 | -$12,436 |
| % Margin | -14.7% | -18.7% | -615.4% | -5,444.2% |
| EPS | -7.32 | -351.36 | -3,523.64 | -9,774.32 |
| % Growth | 97.9% | 90% | 64% | – |
| EPS Diluted | -7.32 | -351.36 | -3,523.64 | -9,520 |
| Weighted Avg Shares Out | 702 | 12 | 8 | 1 |
| Weighted Avg Shares Out Dil | 702 | 12 | 8 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $496 | $812 | $519 | $0 |
| Interest Expense | $9 | $137 | $39 | $329 |
| Depreciation & Amortization | $224 | $149 | $25 | $13 |
| EBITDA | -$5,154 | -$3,824 | -$26,447 | -$12,095 |
| % Margin | -14.8% | -15.9% | -608.5% | -5,294.9% |